· Regulatory update
China accepts application for subcutaneous toripalimab in urothelial carcinoma
China’s National Medical Products Administration accepted for review a supplemental application for subcutaneous toripalimab in combination with disitamab vedotin.
The application concerns first-line treatment for patients with locally advanced or metastatic HER2-expressing urothelial carcinoma.
Read the full company release